What is Senti Bio?
Founded in 2016 and headquartered in South San Francisco, California, Senti Bio is at the forefront of synthetic biology, developing a sophisticated platform designed to program next-generation cell and gene therapies. The company's proprietary gene circuits, constructed from novel DNA sequences, enable cells to sense inputs, compute decisions, and respond dynamically to their environments. This innovative approach positions Senti Bio to revolutionize the development of advanced therapeutic solutions.
How much funding has Senti Bio raised?
Senti Bio has raised a total of $183.2M across 5 funding rounds:
Series A
$53M
Series B
$105M
Debt
$5.2M
Other Financing Round
$10M
Debt
$10M
Series A (2018): $53M with participation from Goodman Capital, New Enterprise Associates, Amgen Business Development, Allen & Company, Pear Ventures, 8VC, Lux Capital, Menlo Ventures, Nest.Bio, Lifeforce Capital Gp I, and Omega Funds
Series B (2021): $105M led by Intel Capital, Matrix Partners China, Mirae Asset Capital Co,Ltd, Leaps by Bayer, and Ridgeback Capital
Debt (2022): $5.2M supported by Bayer
Other Financing Round (2025): $10M featuring Celadon Partners
Debt (2026): $10M, investors not publicly disclosed
Key Investors in Senti Bio
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, based in Menlo Park, California, dedicated to supporting entrepreneurs in building impactful businesses.
Intel Capital
Intel Capital, a division of Intel founded in 1991, invests in innovative startups across various technology sectors including AI, autonomous vehicles, and cloud computing, headquartered in Santa Clara, California.
Matrix Partners China
Matrix Partners China, operating as a venture capital firm since 1977, focuses on investments in software, services, communications equipment, and internet sectors, with its headquarters in San Francisco, California.
What's next for Senti Bio?
With the recent infusion of $10M in a major strategic investment, Senti Bio is poised for accelerated development and market penetration. This substantial backing, part of its overall $183.2M in capital, will likely fuel further research into its synthetic biology platform, expand its therapeutic pipeline, and strengthen its position in the rapidly evolving cell and gene therapy sector. The company's focus on programmable cell therapies suggests a future centered on precision medicine and enhanced treatment efficacy.
See full Senti Bio company page
